Praxis Precision Medicines Inc. PRAX on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal ...
Praxis Precision Medicines (PRAX) traded lower in extended trading after announcing that its Phase 2/3 POWER1 study ...
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measureSecondary measure, the 50% response ...
Praxis plans to initiate two efficacy studies in focal onset seizures. positive data from Ulixa Phase 3 and POC for PRAX-562 in the third quarter should continue to drive momentum in Praxis stock.
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results